Art Unit:

Examiner:

To be determined

To be determined

PATENT

10/593504

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert M. Garbaccio, et al.

Attorney Docket No.

21607P

PCT Appl. No.:

PCT/US05/009198 Filed: 18 March 2005

Filing Date:

September 20, 2006

For:

MITOTIC KINESIN INHIBITORS

Mail Stop: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21607P.

≤By:

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT __September 20, 2006

EXPRESS MAIL NO. EV 660610822 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE APPEARING BELOW

MAILED BY:

DATE:

Respectfully submitted,

David A. Muthard Registration No. 35,297 Attorney for Applicants

Merck & Co., Inc.

P.O. Box 2000 – RY 60-30

Rahway, New Jersey 07065-0907

Telephone No. (732) 594-3903

Date: September 20, 2006